Ocular secures win at the Federal Circuit on its IPR challenge
Clients Ocular Therapeutix, Inc.
Jones Day successfully represented Ocular Therapeutix, Inc., a biopharmaceutical company that develops treatments for the eye, in upholding its inter partes review win against a patent of competitor Mati Therapeutics, Inc. Mati had previously claimed that Ocular's first commercial product Dextenza®, an ophthalmic insert approved by the FDA for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, infringed the patent, and Ocular challenged all of the patent claims in an IPR. The PTAB found all of the claims unpatentable, and Mati appealed. The Federal Circuit unanimously agreed with Ocular and affirmed.
Mati Therapeutics, Inc. v. Ocular Therapeutix, Inc., No. 20-2176 (Fed. Cir.); Ocular Therapeutix v. Mati Therapeutics, Inc., IPR No. 2019-00448 (PTAB)